JAMA Network
About The Study: In adults with mild to moderate hypertension, treatment with zilebesiran, an investigational RNA interference therapeutic, across a range of subcutaneous doses at 3-month or 6-month intervals significantly reduced 24-hour mean ambulatory systolic blood pressure at month three in this phase 2, randomized clinical trial.
Authors: George L. Bakris, M.D., of University of Chicago Medicine, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.0728)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
